Reports

As the novel coronavirus (COVID-19) continues to spread across the world, our analysts are constantly tracking the impact of this rapidly evolving situation on the markets and the consumer purchase behaviours. Thus, our latest estimates and analysis about the current market trends and forecast will exhaustively reflect the effects of this emerging pandemic.

Global Interleukin Inhibitors Market: By Type: L-17, IL-23, IL-1, IL-5, IL-6, Others; By Application: Psoriasis, Psoriatic Arthritis, Rheumatoid Arthritis, Asthma, Inflammatory Bowel Disease, Others; Regional Analysis; Historical Market and Forecast (2017-2027); Market Dynamics; Competitive Landscape; Industry Events and Developments

Global Interleukin Inhibitors Market Outlook

The global interleukin inhibitors market is expected to grow over the forecast period 2022-2027, growing at a CAGR of 13.5%. The interleukin inhibitors market is driven by the highly effective work of interleukin inhibitors in treating autoimmune disease.

 

Interleukin Inhibitors Market

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

 

Properties and Applications

Interleukin inhibitors are referred to as the immunosuppressive agents, which limit the activity of interleukins. Interleukin is a group of cytokines that are synthesized by lymphocytes, macrophages, monocytes, and certain other cells. Their role is to regulate the immune system.

 

Interleukin Inhibitors Market by Application

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

 

The interleukin inhibitors market is segmented based on types and applications.

Based on type, the interleukin inhibitors market is divided into:

  • L-17
  • IL-23
  • IL-1
  • IL-5
  • IL-6
  • Others

Based on application, the interleukin inhibitors market is segmented into:

  • Psoriasis
  • Psoriatic Arthritis
  • Rheumatoid Arthritis
  • Asthma
  • Inflammatory Bowel Disease
  • Others

The EMR report looks into the regional interleukin inhibitors markets like North America, Latin America, Europe, the Middle East and Africa, and the Asia Pacific.

 

Interleukin Inhibitors Market by Region

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

 

Market Analysis

The global interleukin inhibitors market is being driven by the highly effective work of interleukin inhibitors in treating autoimmune disease. The interleukin inhibitors market is aided by the numerous approved interleukin inhibitor molecules for treating autoimmune conditions like rheumatoid arthritis, psoriasis, and Crohn’s disease. Moreover, R&D is in progress over interleukin inhibitor molecules, and clinical trials for late-stage molecules is expected to impact market growth positively. Higher patient adherence to these drugs due to their higher affinity and specificity, as compared to other conventional approved autoimmune therapeutics, is predicted to increase their sales.

 

Competitive Landscape

The report presents a detailed analysis of the following key players in the global interleukin inhibitors market, looking into their capacity, market shares, and latest developments like capacity expansions, plant turnarounds, and mergers and acquisitions:

  • Novartis AG 
  • AbbVie Inc [NYSE: ABBV] 
  • Eli Lilly and Company 
  • Regeneron Pharmaceuticals, Inc. 
  • Johnson & Johnson Services, Inc 
  • F. Hoffmann-La Roche Ltd
  • AstraZeneca 
  • Bausch Health 
  • GlaxoSmithKline plc
  • Teva Pharmaceuticals Industries, Ltd. 
  • Others

The EMR report gives an in-depth insight into the interleukin inhibitors market by providing a SWOT analysis as well as an analysis of Porter’s Five Forces model.

 

REPORT FEATURES DETAILS
Base Year 2020
Historical Period 2017-2021
Forecast Period 2022-2027
Scope of the Report Historical and Forecast Trends, Industry Drivers and Constraints, Historical and
Forecast Market Analysis by Segment- Type, Application, Region
Breakup by Type L-17, IL-23, IL-1, IL-5, IL-6, Others
Breakup by Application Psoriasis, Psoriatic Arthritis, Rheumatoid Arthritis, Asthma, Inflammatory Bowel Disease, Others
Breakup by Region North America, Europe, Asia Pacific, Latin America, Middle East and Africa
Market Dynamics SWOT, Porter's Five Forces, EMR’s Key Indicators for Price and Demand
Competitive Landscape Market Structure, Company Profiles- Company Overview, Product Portfolio, Demographic Reach and Achievements, Certifications
Companies Covered Novartis AG [NOVN (SWX)], AbbVie Inc [ABBV (NYSE)], Eli Lilly and Company [LLY (NYSE)],
Regeneron Pharmaceuticals, Inc. [REGN (NASDAQ)], Johnson & Johnson Services, Inc,
F. Hoffmann-La Roche Ltd [ROG (SWX)], AstraZeneca [AZN (LON)], Bausch Health
[BHC (TSE)], GlaxoSmithKline plc [GSK (LON)], Teva Pharmaceuticals Industries, Ltd. [TEVA (TLV)], Others
Report Price and Purchase Option Explore our purchase options that are best suited to your resources and industry needs.
Delivery Format Delivered as an attached PDF and Excel through email, with an option of receiving an editable PPT, according to the purchase option.

 

*We at Expert Market Research always thrive to give you the latest information. The numbers in the article are only indicative and may be different from the actual report.

1    Preface
2    Report Coverage – Key Segmentation and Scope
3    Report Description

    3.1    Market Definition and Outlook
    3.2    Properties and Applications
    3.3    Market Analysis
    3.4    Key Players
4    Key Assumptions
5    Executive Summary

    5.1    Overview
    5.2    Key Drivers
    5.3    Key Developments
    5.4    Competitive Structure
    5.5    Key Industrial Trends
6    Snapshot
    6.1    Global
    6.2    Regional
7    Industry Opportunities and Challenges
8    Global Interleukin Inhibitors Market Analysis

    8.1    Key Industry Highlights
    8.2    Global Interleukin Inhibitors Historical Market (2017-2021) 
    8.3    Global Interleukin Inhibitors Market Forecast (2022-2027)
    8.4    Global Interleukin Inhibitors Market by Type
        8.4.1    L-17
            8.4.1.1    Market Share
            8.4.1.2    Historical Trend (2017-2021)
            8.4.1.3    Forecast Trend (2022-2027)
        8.4.2    IL-23
            8.4.2.1    Market Share
            8.4.2.2    Historical Trend (2017-2021)
            8.4.2.3    Forecast Trend (2022-2027)
        8.4.3    IL-1
            8.4.3.1    Market Share
            8.4.3.2    Historical Trend (2017-2021)
            8.4.3.3    Forecast Trend (2022-2027)
        8.4.4    IL-5
            8.4.4.1    Market Share
            8.4.4.2    Historical Trend (2017-2021)
            8.4.4.3    Forecast Trend (2022-2027)
        8.4.5    IL-6
            8.4.5.1    Market Share
            8.4.5.2    Historical Trend (2017-2021)
            8.4.5.3    Forecast Trend (2022-2027)
        8.4.6    Others
    8.5    Global Interleukin Inhibitors Market by Application
        8.5.1    Psoriasis
            8.5.1.1    Market Share
            8.5.1.2    Historical Trend (2017-2021)
            8.5.1.3    Forecast Trend (2022-2027)
        8.5.2    Psoriatic Arthritis
            8.5.2.1    Market Share
            8.5.2.2    Historical Trend (2017-2021)
            8.5.2.3    Forecast Trend (2022-2027)
        8.5.3    Rheumatoid Arthritis
            8.5.3.1    Market Share
            8.5.3.2    Historical Trend (2017-2021)
            8.5.3.3    Forecast Trend (2022-2027)
        8.5.4    Asthma 
            8.5.4.1    Market Share
            8.5.4.2    Historical Trend (2017-2021)
            8.5.4.3    Forecast Trend (2022-2027)
        8.5.5    Inflammatory Bowel Disease 
            8.5.5.1    Market Share
            8.5.5.2    Historical Trend (2017-2021)
            8.5.5.3    Forecast Trend (2022-2027)
        8.5.6    Others
    8.6    Global Interleukin Inhibitors Market by Region
        8.6.1    Market Share
            8.6.1.1    North America
            8.6.1.2    Europe
            8.6.1.3    Asia Pacific
            8.6.1.4    Latin America
            8.6.1.5    Middle East and Africa
9    Regional Analysis
    9.1    North America
        9.1.1    Historical Trend (2017-2021)
        9.1.2    Forecast Trend (2022-2027)
        9.1.3    Breakup by Country
            9.1.3.1    United States of America 
            9.1.3.2    Canada
    9.2    Europe
        9.2.1    Historical Trend (2017-2021)
        9.2.2    Forecast Trend (2022-2027)
        9.2.3    Breakup by Country 
            9.2.3.1    United Kingdom
            9.2.3.2    Germany
            9.2.3.3    France
            9.2.3.4    Italy
            9.2.3.5    Others
    9.3    Asia Pacific
        9.3.1    Historical Trend (2017-2021)
        9.3.2    Forecast Trend (2022-2027)
        9.3.3    Breakup by Country
            9.3.3.1    China
            9.3.3.2    Japan
            9.3.3.3    India
            9.3.3.4    ASEAN
            9.3.3.5    Australia
            9.3.3.6    Others
    9.4    Latin America
        9.4.1    Historical Trend (2017-2021)
        9.4.2    Forecast Trend (2022-2027)
        9.4.3    Breakup by Country
            9.4.3.1    Brazil
            9.4.3.2    Argentina
            9.4.3.3    Mexico
            9.4.3.4    Others
    9.5    Middle East and Africa
        9.5.1    Historical Trend (2017-2021)
        9.5.2    Forecast Trend (2022-2027)
        9.5.3    Breakup by Country
            9.5.3.1    Saudi Arabia
            9.5.3.2    United Arab Emirates
            9.5.3.3    Nigeria
            9.5.3.4    South Africa
            9.5.3.5    Others
10    Market Dynamics
    10.1    SWOT Analysis
        10.1.1    Strengths
        10.1.2    Weaknesses
        10.1.3    Opportunities
        10.1.4    Threats
    10.2    Porter’s Five Forces Analysis
        10.2.1    Supplier’s Power
        10.2.2    Buyer’s Power
        10.2.3    Threat of New Entrants
        10.2.4    Degree of Rivalry
        10.2.5    Threat of Substitutes
    10.3    EMR’s Key Indicators for Demand
    10.4    EMR’s Key Indicators for Price
11    Value Chain Analysis
12    Competitive Landscape

    12.1    Market Structure
    12.2    Company Profiles
        12.2.1    Novartis AG
            12.2.1.1    Company Overview
            12.2.1.2    Product Portfolio
            12.2.1.3    Demographic Reach and Achievements
            12.2.1.4    Certifications
        12.2.2    AbbVie Inc.
            12.2.2.1    Company Overview
            12.2.2.2    Product Portfolio
            12.2.2.3    Demographic Reach and Achievements
            12.2.2.4    Certifications
        12.2.3    Eli Lilly and Company
            12.2.3.1    Company Overview
            12.2.3.2    Product Portfolio
            12.2.3.3    Demographic Reach and Achievements
            12.2.3.4    Certifications
        12.2.4    Regeneron Pharmaceuticals, Inc.
            12.2.4.1    Company Overview
            12.2.4.2    Product Portfolio
            12.2.4.3    Demographic Reach and Achievements
            12.2.4.4    Certifications
        12.2.5    Johnson and Johnson Services, Inc.
            12.2.5.1    Company Overview
            12.2.5.2    Product Portfolio
            12.2.5.3    Demographic Reach and Achievements
            12.2.5.4    Certifications
        12.2.6    F. Hoffmann-La Roche Ltd.
            12.2.6.1    Company Overview
            12.2.6.2    Product Portfolio
            12.2.6.3    Demographic Reach and Achievements
            12.2.6.4    Certifications
        12.2.7    AstraZeneca
            12.2.7.1    Company Overview
            12.2.7.2    Product Portfolio
            12.2.7.3    Demographic Reach and Achievements
            12.2.7.4    Certifications
        12.2.8    Bausch Health
            12.2.8.1    Company Overview
            12.2.8.2    Product Portfolio
            12.2.8.3    Demographic Reach and Achievements
            12.2.8.4    Certifications
        12.2.9    GlaxoSmithKline plc
            12.2.9.1    Company Overview
            12.2.9.2    Product Portfolio
            12.2.9.3    Demographic Reach and Achievements
            12.2.9.4    Certifications
        12.2.10    Teva Pharmaceuticals Industries, Ltd.
            12.2.10.1    Company Overview
            12.2.10.2    Product Portfolio
            12.2.10.3    Demographic Reach and Achievements
            12.2.10.4    Certifications
        12.2.11    Others
13    Industry Events and Developments


List of Figures and Tables

1.    Global Interleukin Inhibitors Market: Key Industry Highlights, 2017 and 2027
2.    Global Interleukin Inhibitors Historical Market: Breakup by Type (USD Million), 2017-2021
3.    Global Interleukin Inhibitors Market Forecast: Breakup by Type (USD Million), 2022-2027
4.    Global Interleukin Inhibitors Historical Market: Breakup by Application (USD Million), 2017-2021
5.    Global Interleukin Inhibitors Market Forecast: Breakup by Application (USD Million), 2022-2027
6.    Global Interleukin Inhibitors Historical Market: Breakup by Region (USD Million), 2017-2021
7.    Global Interleukin Inhibitors Market Forecast: Breakup by Region (USD Million), 2022-2027
8.    North America Interleukin Inhibitors Historical Market: Breakup by Country (USD Million), 2017-2021
9.    North America Interleukin Inhibitors Market Forecast: Breakup by Country (USD Million), 2022-2027
10.    Europe Interleukin Inhibitors Historical Market: Breakup by Country (USD Million), 2017-2021
11.    Europe Interleukin Inhibitors Market Forecast: Breakup by Country (USD Million), 2022-2027
12.    Asia Pacific Interleukin Inhibitors Historical Market: Breakup by Country (USD Million), 2017-2021
13.    Asia Pacific Interleukin Inhibitors Market Forecast: Breakup by Country (USD Million), 2022-2027
14.    Latin America Interleukin Inhibitors Historical Market: Breakup by Country (USD Million), 2017-2021
15.    Latin America Interleukin Inhibitors Market Forecast: Breakup by Country (USD Million), 2022-2027
16.    Middle East and Africa Interleukin Inhibitors Historical Market: Breakup by Country (USD Million), 2017-2021
17.    Middle East and Africa Interleukin Inhibitors Market Forecast: Breakup by Country (USD Million), 2022-2027
18.    Global Interleukin Inhibitors Market Structure

Key Questions Answered in the Report

The global interleukin inhibitors market is projected to grow at a CAGR of 13.5% between 2022 and 2027.

The major drivers of the market include the research and development activities, rise in awareness amongst the consumers and physicians, rise in the prevalence of chronic inflammatory diseases such as psoriasis, arthritis, rise in FDA approvals for novel drugs and therapies, increase in the prevalence of autoimmune diseases, and high adoption of advanced treatment options.

The highly effective work of interleukin inhibitors in treating autoimmune diseases and higher patient adherence are the key industry trends propelling the market's growth.

The major regions in the industry are North America, Latin America, the Middle East and Africa, Europe, and the Asia Pacific.

Based on type, the interleukin inhibitors market is divided into L-17, IL-23, IL-1, IL-5, and IL-6, among others.

The major applications include psoriasis, psoriatic arthritis, rheumatoid arthritis, asthma, and inflammatory bowel disease, among others.

The major players in the industry are Novartis AG, AbbVie Inc, Eli Lilly and Company, Regeneron Pharmaceuticals, Inc., Johnson & Johnson Services, Inc, F. Hoffmann-La Roche Ltd, AstraZeneca, Bausch Health, GlaxoSmithKline plc, and Teva Pharmaceuticals Industries, Ltd., among others.

Analyst Review

The global interleukin inhibitors market has been driven by the highly effective work of interleukin inhibitors in treating autoimmune diseases in the historical period. Aided by the rise in awareness amongst the consumers and physicians and rise in the prevalence of chronic inflammatory diseases, the market is expected to witness further growth in the forecast period of 2022-2027, growing at a CAGR of 13.5%.

EMR's meticulous research methodology delves deep into the market, covering the macro and micro aspects of the industry. Based on type, the interleukin inhibitors market is divided into L-17, IL-23, IL-1, IL-5, and IL-6, among others. The major applications include psoriasis, psoriatic arthritis, rheumatoid arthritis, asthma, and inflammatory bowel disease, among others. The major regional markets for the interleukin inhibitors market are North America, Europe, the Asia Pacific, Latin America, and the Middle East and Africa. The major players in the industry are Novartis AG, AbbVie Inc, Eli Lilly and Company, Regeneron Pharmaceuticals, Inc., Johnson & Johnson Services, Inc, F. Hoffmann-La Roche Ltd, AstraZeneca, Bausch Health, GlaxoSmithKline plc, and Teva Pharmaceuticals Industries, Ltd., among others.

EMR's research methodology uses a combination of cutting-edge analytical tools and the expertise of their highly accomplished team, thus, providing their customers with market insights that are accurate, actionable and help them remain ahead of their competition.

Purchase Full Report

Mini Report

$1499
  • Selected Sections, One User
  • Printing Not Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Single User License

$2699
  • All Sections, One User
  • One Print Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Five User License

$3699
  • All Sections, Five Users
  • Five Prints Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Corporate License

$4699
  • All Sections, Unlimited Users
  • Unlimited Prints Allowed
  • Email Delivery in PDF + Excel
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Any Question? Speak With An Analyst

Contact Analyst

View A Sample

Request Sample

Did You Miss Anything, Ask Now

Request Customisation
Why Expert Market Research?

RIGHT PEOPLE

We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.

RIGHT METHODOLOGY

We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.

RIGHT PRICE

We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.

RIGHT SUPPORT

Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.

Similar Reports





NEWSLETTER